Congenital cytomegalovirus (cCMV) surveillance: a recently added threat in the Surveillance for Emerging Threats to Pregnant People and Infants Network (SET-NET)

Presented by: Ashrita Rau, MPH |Tory Kaye, MPH | Kelley Raines, MPH









- Summarize the status of state-level cCMV surveillance in the United States
- Describe the goals and cross-jurisdictional outcomes of the cCMV surveillance pilot within SET-NET
- > Report findings from the first year of the SET-NET pilot
 - Across all participating jurisdictions
 - In-Depth report from Minnesota

> Questions and answers

Status of state-level cCMV surveillance in the United States

Status of state-level cCMV surveillance in the U.S.

Eleven* states systematically collect cCMV surveillance data:

New Jersey (1985), Colorado (1987), Illinois (1989), Oklahoma (1994), Delaware (2003), Michigan (2011), Utah (2013), Connecticut (2016), New York (2016), Virginia (2020), Minnesota (2023)

Received: 8 July 2022 Revised: 18 August 2022 Accepted: 7 September 2022 DOI: 10.1002/bdr2.2098 Birth Defects Single for the second for

¹ASRT, Inc., Contracting agency to Division of Viral Diseases, Nations Center for Immunization and Ress Diseases, Centers for Disease Cont Prevention, Atlanta, Georgia, USA ²Division of Viral Diseases, Natior Center for Immunization and Ress Diseases, Centers for Disease Cont Prevention, Atlanta, Georgia, USA

News Release Feb. 8, 2023

Contact information

Minnesota becomes first state to screen all newborns for congenital cytomegalovirus Common virus can lead to hearing loss in about 20% of diagnosed cases

Earlier this week the Minnesota Department of Health (MDH) became the first state in the nation to screen all newborns for congenital cytomegalovirus (cCMV), a common viral infection that can have serious health effects for children if not detected early.


Status cCMV Surveillance: Methods of Surveillance

Method of Ascertainment/Reporting:

- Laboratory results (DE, UT, CT, VA, MN)
- Diagnostic codes (NJ, CO, IL, OK, NY)
- Reported diagnosis (NJ, CO, IL, NY)

cCMV Screening Practices:

- Targeted hearing screening (UT, CT, NY, VA)
- Universal screening (MN)
- High-risk symptom screening (UT)



Status of cCMV Surveillance: Data Elements Collected

	Data Elements Collected					Data	Data	
State	Demographics	Clinical Signs	Laboratory	Treatment	Long-term Outcomes	Maternal	Analysis Capacity¶	Disseminated ⁺⁺
New Jersey	Х	х					х	
Colorado	Х					х	х	
Illinois	Х	Х		Х		X§	х	Х
Oklahoma	Х	Х				X§	х	
Delaware	Х	х	Х			X§	х	
Michigan	Х	х				х	х	Х
Utah	Х	Х	Х	Х	Х	X§	Х	Х
Connecticut	Х	х	х	Х		Х	х	
New York	Х					х	х	
Virginia	Х	х	х	х		х	х	Х
Minnesota	Х	х	Х	х	Х	х	х	Х
Total	11	9	5	5	2	10	11	5

§ Maternal infection data collected along with maternal demographics

¶ Includes states who showed the capacity to analyze birth prevalence

⁺⁺Includes states who developed summaries, reports, or visualizations that they reported sharing

Status of cCMV Surveillance: Challenges Reported



Limited Personnel



Delays in Case Data Submission



Limited Funding



Incomplete Reporting



Complex and Siloed Data Systems



CSTE: Council of State and Territorial Epidemiologists

What was approved by CSTE at the annual June meeting (effective Jan 2024):

- 1. Reporting criteria
- 2. Case classifications based on clinical and laboratory evidence:

Case Classification	Laboratory Evidence	Clinical Evidence
Confirmed cCMV infection	Confirmatory	No
Confirmed cCMV Disease	Confirmatory	Yes
Probable cCMV disease	Presumptive	Yes



23-ID-02

Committee: Infectious Disease

Title: Standardized Surveillance Case Definitions for Congenital Cytomegalovirus (cCMV) Infection and Disease

 \Box Check this box if this position statement is an update to an existing standardized surveillance case definition and include the most recent position statement number here: <u>N/A</u>.

Synopsis:

- This position statement creates standardized case definitions for cCMV infection and disease.
- Standardized case definitions for cCMV infection and disease are needed because multiple jurisdictions in the United States are conducting cCMV screening and surveillance activities but are using various methods and inclusion criteria for case ascertainment, reporting, and classification. As more jurisdictions pass legislation for newborm screening for cCMV, standardized case definitions for cCMV infection and disease can be used to understand the epidemiology of cCMV and compare trends across the United States.
- Case ascertainment criteria include laboratory criteria (the detection of CMV in neonatal urine, saliva, whole blood, or cerebrospinal fluid specimens, in amniotic fluid specimens, or umbilical cord or autopsy specimens), vital records criteria (infant death certificates), and healthcare records criteria (e.g., using ICD-10 diagnostic codes).
- · Case classification criteria include clinical and laboratory criteria.
- Case classifications include confirmed cCMV infection, confirmed cCMV disease, and probable cCMV disease.

I. Statement of the Problem

Cytomegalovirus (CMV) infection during pregnancy can cause stillbirth, infant death, and a myriad of birth defects.^{1,3} In the United States (U.S.), approximately 1 in 200 babies is born with congenital CMV (cCMV) infection, one out of of these babies will present with clinical signs of cCMV disease in the neonatal period and/or have long-term health conditions.⁴ cCMV is the most common infectious cause of developmental disabilities and non-genetic sensorineural

Reporting Criteria

- Laboratory
 - CMV-positive PCR or culture of urine, saliva, whole blood, dried blood spot, CSF

or

- detection of CMV antigen in other specimens (umbilical cord, autopsy specimen, whole blood)
- Vital Records
 - An infant aged one year or less whose death certificate lists cCMV or CMV as an underlying cause of, or significant condition contributing to, death
- Healthcare Record
 - A child aged 6 years or younger with a diagnosis of cCMV infection (P35.1) or
 - An infant aged 45 days or younger with a diagnosis of CMV disease (B25.x)

Laboratory Evidence

C	onfirma	tory (C)		Presumptive (P)			
 Birth	21 da	ays			 42 days		
Specimens	NAAT	Culture	Antigen Test	Specimens	NAAT	Culture	Antigen Test
Urine	с	с		Urine	Р	Р	
Whole blood	с	с	С	Whole blood	Р	Р	Р
Dried blood spot	с						
CSF	с	с		CSF	Р	Р	
Saliva*	Р	Р		Saliva*	Р	Р	

*Presumptive in absence of negative urine test; requires confirmation with urine test <21 days to become "confirmatory"

Clinical Evidence


- An infant with at least one of the following clinical signs **during the neonatal period**:
 - \circ Hepatomegaly
 - Splenomegaly
 - Petechial rash or purpura
- A child aged **6 years or younger** with one or more of the following permanent conditions:
 - Microcephaly
 - Brain imaging abnormalities consistent with cCMV
 - Sensorineural hearing loss
 - Seizures
 - \circ Cerebral palsy
 - \circ Chorioretinitis
 - Vision impairment, resulting from conditions consistent with cCMV

Goals and outcomes of the cCMV surveillance pilot within SET-NET

cCMV SET-NET Surveillance Pilot: What is SET-NET?

Surveillance for Emerging Threats to Pregnant People and Infants Network

- State, local, and territorial health departments work with CDC to identify the impact of emerging health threats on pregnant people & infants
- Collects information on five infectious diseases, including cCMV



Eight jurisdictions participating in the cCMV SET-NET Pilot:

- Year 1 (2022-2024): Minnesota, Utah, New York, New Jersey & Iowa
- Year 2 (2023-2024): Plus, LA County, Virginia, Illinois

Year 1 (2022-2023) Objectives:

- Identify, develop, and evaluate surveillance methods for cCMV
- Assess trends in cCMV infection and disease (aggregate data submitted)

Year 2 (2023-2024) Objectives:


- Identify, develop, and evaluate surveillance methods for cCMV
- Assess trends in cCMV infection and disease (caselevel data submitted)

INPUTS	ACTIVITIES	SHORT-TERM OUTCOMES	INTERMEDIATE- TERM OUTCOMES	LONG-TERM OUTCOMES	
•Funding •CDC and jurisdictional	Identify, develop, and evaluate methods for cCMV surveillance in participating jurisdictions	Improved understanding of cCMV surveillance processes and attributes in participating jurisdictions	Informed cCMV surveillance processes and best practices	Improved	
technical expertise •SET-NET surveillance system	Assess trends in cCMV infection and disease in participating jurisdictions	Enhanced cCMV surveillance processes in participating jurisdictions	Increased use of a CSTE cCMV case definition by jurisdictions	understanding of multi-jurisdictiona trends in cCMV infection and disease	
•SET-NET's pre-existing partnerships with state health departments	Provide ad hoc support as requested by jursidictions	Improved understanding of the acceptability and feasibility of implementing a CSTE cCMV case definition in participating jurisdictions	Improved quality of cCMV surveillance data	Informed public health strategies to prevent, detect, and treat cCMV-associated disabilities	
•Partnership between NCIRD and NCBDDD	Facilitate dialogue between jursidictions	Increased use of cCMV surveillance data for public health action in participating jurisdictions	cCMV surveillance data for public health action at multi-jurisdictional level		

Eight jurisdictions participating in the cCMV SET-	INPUTS	ACTIVITIES	SHORT-TERM OUTCOMES	INTERMEDIATE- TERM OUTCOMES	LONG-TERM OUTCOMES
NET Pilot					
 Year 1 (2022-2024): Minnesota, Utah, New 	•Funding •CDC and jurisdictional	Identify, develop, and evaluate methods for cCMV surveillance in participating jurisdictions	Improved understanding of cCMV surveillance processes and attributes in participating jurisdictions	Informed cCMV surveillance processes and best practices	Improved
York, New Jersey & Iowa	technical expertise			lange of a	understanding of multi-jurisdictional
• Year 2 (2023-2024): Plus, LA County, Virginia		Assess trends in cCMV infection and disease in	Enhanced cCMV surveillance processes in	Increased use of a CSTE cCMV case definition by jurisdictions	trends in cCMV infection and disease
Illinois	system	participating jurisdictions	participating jurisdictions	Junisuletions	
Year 1 (2022-2023) Objectives:	•SET-NET's pre-existing partnerships with state	Provide ad hoc support as requested by	Improved understanding of the acceptability and feasibility of implementing a	Improved quality of cCMV surveillance data	Informed public health strategies
 Identify, develop, and evaluate surveillance 	health	jursidictions	CSTE cCMV case definition in participating jurisdictions		to prevent, detect, and treat
methods for cCMV	•Partnership			Increased use of cCMV surveillance data for public	cCMV-associated disabilities
 Assess trends in cCMV infection and disease 	between NCIRD and NCBDDD	Facilitate dialogue between jursidictions	Increased use of cCMV surveillance data for public health action in participating	health action at multi-jurisdictional	
(aggregate data submitted)			jurisdictions		

Outcome #1: Improved understanding of cCMV surveillance methods and attributes

Identify and evaluate jurisdictions' cCMV surveillance methods by collecting information on:



Surveillance Processes

Acceptability and Simplicity of Surveillance **Data Completeness**

Surveillance Data (Aggregate)


Surveillance Processes as of July 2023:

Surveillance Criteria	Utah	Minnesota	New Jersey	New York*	lowa*
Conducting cCMV Surveillance	Yes	Yes	Yes	Yes	No
Method of Ascertainment/ Reporting	Laboratory Results	Laboratory Results or Diagnostic Code	Laboratory Results, Diagnostic Code, or Clinical Report	Diagnostic Code	N/A
cCMV Case Classification	Confirmed: Positive PCR or viral culture test (Urine, Saliva, Blood, CSF) before 21 days of of life	Confirmed: Positive NAAT from urine, urine, whole blood, or CSF within 21 21 days of life. Probable: Positive NAAT from saliva saliva within 42 days and NAAT from from urine, whole blood, or CSF within 22 – 42 days of life with clinical signs. (CSTE Case Definition) Definition) niversal screening of cCMV with corresponding	Confirmed: Clinical report, Diagnostic code, or Positive PCR PCR test (Urine, Saliva, Blood) before before 21 days of life life	Confirmed: Diagnostic Diagnostic Code	N/A

surveillance

Reports on Simplicity of cCMV surveillance:

Data Collection



Multiple data sources and complex/unstandardized abstraction processes make data collection challenging **Data Management**



System maintenance was reported as fairly simple and can be easily streamlined and/or outsourced

Reports on Acceptability of cCMV surveillance:

Case Ascertainment/Reporting

Timeliness of Reporting





cCMV Awareness




Statutes are key for reporting compliance and case ascertainment ELR are received in 1-2 days by MN and UT. Timeliness of non-automated systems is dependent on clinician awareness. cCMV awareness has been low early in screening/surveillance, leading to the need for consistent training

Data Collected for cCMV Surveillance (MN and UT)*:


Category of Data	Data Sources	Data Elements	Status of Data Collection^	
Laboratory Records	Electronic lab records, newborn	Infants Testing Results	Systematically collected (MN and UT mandate reporting via lab confirmation)	
	screening reports, clinician reports	Prenatal Testing Results	Not systematically collected	
		Demographics	Systematically Collected	
Maternal Information	Infant medical records, vital records	Obstetrics Information	Not Systematically Collected	
		Ultrasound Results	Not Systematically Collected	
		cCMV Clinical Signs	Systematically Collected	
Pregnancy and Birth	Medical records, vital records, early hearing and detection intervention system, birth defects system	Hearing Screening Results	Systematically Collected	
Outcomes		Adverse Outcomes	Systematically Collected	
		Treatment Data	Systematically Collected	
		Referrals (i.e., Ophthalmology and audiology)	Systematically Collected	
		Ophthalmologic Evaluation Data	Systematically Collected	
Long-Term Follow-Up (MN collected > 1 year; UT	Infant medical records, vital records, early hearing and	Audiologic Evaluation Data	Systematically Collected	
on-going follow-up)	detection intervention system	Brain Imaging Data	Systematically Collected	
		Treatment Outcomes	Systematically Collected	
*C		Developmental Screening Data	Not Systematically Collected	

*Summary for MN and UT only as only predictive estimated reported by other participating jurisdictions ^Systematically collected was defined as completeness >80% for variables collected within each data element

Jurisdiction	Case Ascertainment	Period for Reported cCMV Cases	Annual Number of Reported cCMV Cases	Annual Prevalence per 1,000 Live Births
Utah	Targeted Hearing and High-Risk Screening	2013 - 2023	4 - 28	0.12 – 0.60
New Jersey	Diagnostic Codes, Clinical Reports	2018 - 2022	16 - 26	0.16 – 0.26
Minnesota	Universal Screening	2023	29	1.96



UT MN



cCMV SET-NET Surveillance Pilot: Key Activities (Year 1)

Outcome #2: Enhanced cCMV surveillance processes in participating jurisdictions



Two jurisdictions started cCMV surveillance



Jurisdictions established data use agreements



One jurisdictions evaluated and backfilled missing cCMV surveillance



One jurisdiction surveyed the processes of targeted screening hospitals



Two jurisdictions added/in the process of adding cCMV to the communicable disease rule



Jurisdictions developed cCMV specific databases

Jurisdictions collaborated with programs across the HD for cCMV surveillance



Jurisdictions shared surveillance best practices with each other

Eight jurisdictions participating in the cCMV SET-	INPUTS	ACTIVITIES	SHORT-TERM OUTCOMES	INTERMEDIATE- TERM OUTCOMES	LONG-TERM OUTCOMES
 NET Pilot: Year 1 (2022-2024): Minnesota, Utah, New York, New Jersey & Iowa 	•Funding •CDC and jurisdictional	Identify, develop, and evaluate methods for cCMV surveillance in participating jurisdictions	Improved understanding of cCMV surveillance processes and attributes in participating jurisdictions	Informed cCMV surveillance processes and best practices	Improved understanding of
 Year 2 (2023-2024): Plus LA County, Virginia Illinois 	•SET-NET surveillance system	Assess trends in cCMV infection and disease in participating jurisdictions	Enhanced cCMV surveillance processes in participating jurisdictions	Increased use of a CSTE cCMV case definition by jurisdictions	multi-jurisdictional trends in cCMV infection and disease
Year 1 (2022-2023) Objectives:	•SET-NET's pre-existing partnerships with state health departments	Provide ad hoc support as requested by jursidictions	Improved understanding of the acceptability and feasibility of implementing a CSTE cCMV case definition in participating jurisdictions		Informed public health strategies to prevent, detect, and treat cCMV-associated
 Identify, develop, and evaluate surveillance methods for cCMV Assess trends in cCMV infection and disease 	•Partnership between NCIRD and NCBDDD	Facilitate dialogue between jursidictions	Increased use of cCMV surveillance data for public health action in participating jurisdictions	Increased use of cCMV surveillance data for public health action at multi-jurisdictional level	disabilities
(aggregate data submitted)					



Minnesota Surveillance Process & Attributes

Case ascertainment in Minnesota

Newborn screening

Death records


Clinical

test

results




cCMV surveillance in Minnesota



- Statewide, population-based
- Reporting criteria
 - **o cCMV/CMV listed as cause of death**
 - Positive laboratory test ≤ 90 days of life
- Case definition:
 - Resident of MN at birth
 - **OBorn on/after February 6, 2023**
 - **OMeets CSTE case definition for cCMV**
 - \circ Initial data collection complete



Preliminary surveillance data in Minnesota February 6–August 5, 2023






We only know what we know


cCMV is not a reportable disease (yet)

- Cannot mandate clinical reporting
- O 3 of 6 clinical labs voluntarily reporting positive results
- With universal screening, will providers assume we already know about the case?





Targeted screening still useful



- Even after mandated reporting, asymptomatic babies are unlikely to be tested and reported
- Targeted screening can pick up more





Feasibility & Acceptability of Applying a Case Definition

• Laboratory criteria

- Confirmatory: 72 (92%)
- Dried blood spot (DBS) collected ≤ 21 days, no negative urine


• Presumptive: 2 (3%)

- Dried blood spot collected 21 ≤ 42 days, no negative urine

• Does not meet: 4 (5%)


- Positive blood or saliva with a negative urine (and negative DBS)
- Positive urine with prior negative urine, whole blood, DBS
- Positive DBS with negative confirmatory urine







Individual infant

Clinical criteria
 Yes, 10 (13%)
 No, 68 (87%)






Applying the CSTE surveillance case definition



Applying the CSTE surveillance case definition

72 (92%) of ascertained cases meet the CSTE standardized surveillance case definition





Feasibility of standardized case definition

- Feasible from an epidemiological/surveillance standpoint
 - Acceptance that public health data are messy
 - All information collected by newborn screening followup

• Resource intensive

O Medical record abstraction takes 1-3 hours per infant



Feasibility of standardized case definition

- Brain imaging data collection
 - \circ Complex medical information
 - "Brain imaging abnormalities consistent with cCMV, such as intracranial calcifications,..."
- Hard to tell whether something was due to cCMV or alternative diagnosis
 - o "In the absence of a more likely alternative etiology:"



Acceptability of standardized case definition

- Difficult from newborn screening which has a more clinical perspective
 - Asymptomatic, mildly symptomatic, moderate/severely symptomatic do not align well with case definition
 - Dried blood spot positive without confirmatory specimen
 - Confirmed surveillance case
 - "No follow-up" for screening- not useful for performance metrics



Acceptability of standardized case definition


- Separate screening and surveillance
 - Newborn screening would be a data source and aid in defining cohort





Use of Surveillance Data for Public Health Action

Typical infectious disease case ascertainment



- Only symptomatic cases are identified and reported to health departments
- Follow-up is defined



Use of infectious disease surveillance


- Surveillance data support public health action
- Most well known for outbreak detection
 - Mostly acute diseases
- Identify at-risk groups
- Estimate burden
- Public health action is quick

-Remove the implicated source = stop the outbreak

-Protect against additional illness




cCMV with universal screening case ascertainment





cCMV with universal screening





Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	
Public health action is quick	
Remove the implicated source = stop the outbreak	
Protect people from getting sick	
Identify at-risk groups; estimate disease burden	



Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	Small proportion are acute onset
Public health action is quick	
Remove the implicated source = stop the outbreak	
Protect people from getting sick	
Identify at-risk groups; estimate disease burden	



Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	Small proportion are acute onset
Public health action is quick	Limited public health action so far
Remove the implicated source = stop the outbreak	
Protect people from getting sick	
Identify at-risk groups; estimate disease burden	



Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	Small proportion are acute onset
Public health action is quick	Limited public health action so far
Remove the implicated source = stop the outbreak	Other children are a well known source
Protect people from getting sick	
Identify at-risk groups; estimate disease burden	



Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	Small proportion are acute onset
Public health action is quick	Limited public health action so far
Remove the implicated source = stop the outbreak	Other children are a well known source
Protect people from getting sick	
Identify at-risk groups; estimate disease burden	



Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	Small proportion are acute onset
Public health action is quick	Limited public health action so far
Remove the implicated source = stop the outbreak	Other children are a well known source
Protect people from getting sick	
Identify at-risk groups; estimate disease burden	





Comparison to petting zoos

Take home memories, not germs



While getting your selfies with the animals:

No food, drinks, bottles, or pacifiers in the animal area

Don't touch your hands to your face or mouth

Watch children closely





Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	Small proportion are acute onset
Public health action is quick	Limited public health action so far
Remove the implicated source = stop the outbreak	Other children are a well known source
Protect people from getting sick	Educate to protect health
Identify at-risk groups; estimate disease burden	



Typical Infectious Disease Surveillance	cCMV Surveillance
Most well known for outbreak detection	CMV is ubiquitous, does not occur in outbreaks
Mostly acute diseases	Small proportion are acute onset
Public health action is quick	Limited public health action so far
Remove the implicated source = stop the outbreak	Other children are a well known source
Protect people from getting sick	Educate to protect health
Identify at-risk groups; estimate disease burden	Identify at-risk groups; estimate disease burden



Using surveillance data in Minnesota

- cCMV consortium, hear from families and providers
- Congenital community of practice at MDH





Using multistate surveillance data

- How can multistate surveillance help situations like these?
 - Increase conversation about inherent risks
 - Pool data collected to increase knowledge
 - Lead to new or improved public health action







cCMV Surveillance: What's Next?

- Develop cCMV surveillance best practices
- Enhance awareness, implementation, and evaluation of the CSTE cCMV case definition
- Evaluate and improve cCMV surveillance data quality
- Increase use of cCMV surveillance data for public health action